People are more Drug Conscious rather than Health Conscious.
Some even go to the extent of associating Drugs and serious ailments with Social Acceptability and a matter of Pride indicative of Status.
One can come across people saying, I had a Heart attack,Stroke have High Cholesterol,Diabetes, Kidney Malfunction;taking Lipitor,Statins “
They forget that having a disease is an indication of Ill Health and as such is something to be ashamed of.
Gulping Drugs with Esoteric names backed by high-powered advertising, people seem to enjoy taking Drugs.
The dangerous aspect is the side effects which are worse than the Diseases.
Another surprising fact is that the Drugs that bring in the Highest Revenue to the Drug Manufacturers are the Drugs of dubious Curative Nature, but are of guaranteed ,severe, at times irreversible side effect causing!
Look at these maximum earners.
Pfizer‘s (NYSE:PFE ) cholesterol-lowering drug Lipitor is a perfect example. Over the course of its patent protection period, Lipitor brought in $131 billion in cumulative sales – more than double the second-most successful drug of all time,Bristol-Myers Squibb‘s Plavix, which totaled around $60 billion. Although Pfizer’s pipeline is diverse, Lipitor was single-handedly able to deliver the cash flow necessary for Pfizer to grow its pipeline into what it is today.
With that in mind, I propose we examine the current three best-selling drugs in the world and see whether they have characteristics that would make them cash-flow cows like Pfizer’s Lipitor or if their gains now are soon to be fleeting.
One thing to keep in mind is that we’re getting into the heart of earnings season, so the drug-sale figures presented here will be extrapolated estimates based on results through the first half of the year.
Humira — estimated 2013 sales: $10.1 billion.
Humira is currently the best-selling drug in the world, bringing in $4.85 billion for AbbVie(NYSE: ABBV ) through the first six months of the year and helping generate $349 million global partnership sales revenue for Eisai as of the end of its fiscal year in March. It’s also a driving force behind AbbVie’s income investor-friendly 3.3% yield.
In the case of Humira, it may be easier to look at what it isn’t approved for than what it is! The drug has seven separate anti-inflammatory indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, plague psoriasis, and Crohn’s disease, and most recently it was approved a year ago for ulcerative colitis. But even the best-selling drug in the world isn’t perfect – the FDA’s panel recommended against approving Humira by a vote of 12-1 for the treating an inflammatory disease of the spine.”
Of these Lipitor,
‘Ranbaxy, the international Drug Manufacturer admitted in the United States to charges of making and distributing adulterated drugs at its two Indian plants of Paonta Sahib and Dewas and agreed to a $500 million settlement.”(http://ramanan50.wordpress.com/2013/05/24/ranbaxy-sold-adulterated-drugs-liptor-admits/)..
The best-selling statin is atorvastatin which in 2003 became the best-selling pharmaceutical in history, with Pfizerreporting sales of US$12.4 billion in 2008., is now fond to be a cause for Breast Cancer in women.(http://ramanan50.wordpress.com/2013/07/20/cholesterol-control-drug-causes-cancer)
Check with your doctor immediately if any of the following side effects occur while taking clopidogrel:
- Chest pain
- collection of blood under the skin
- deep, dark purple bruise
- itching, pain, redness, or swelling
- pain in general
- red or purple spots on the skin, varying in size from pinpoint to large bruises
- painful or difficult urination
- shortness of breath
- vomiting of blood or material that looks like coffee grounds.
- Humira Side Effects.
SERIOUS INFECTIONS AND MALIGNANCY
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death [see WARNINGS ANDPRECAUTIONS]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue HUMIRA if a patient develops a serious infection or sepsis.
Reported infections include
- Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HUMIRA use and during therapy. Initiate treatment for latent TB prior to HUMIRA use.
- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.
Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients with chronic or recurrent infection.
Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see WARNINGS AND PRECAUTIONS andADVERSE REACTIONS].
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA [see WARNINGS AND PRECAUTIONS]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see WARNINGS AND PRECAUTIONS].”